Sujal Ghosh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sujal Ghosh has a total of 286 co-authors. Here are the top co-authors by number of shared publications:
Arndt Borkhardt
Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich-Heine-University, University Hospital Düsseldorf, Moorenstraße 5, 40225, Duesseldorf, Germany
8 shared publicationsHans-Jürgen Laws
Division of Pediatric Stem Cell Therapy, Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany
8 shared publicationsFriedhelm R. Schuster
Division of Pediatric Stem Cell Therapy, Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany
4 shared publicationsRoland Meisel
Division of Pediatric Stem Cell Therapy, Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Center of Child and Adolescent Health, Heinrich-Heine-University, Düsseldorf, Germany
4 shared publicationsTim Niehues
Centre for Child and Adolescent Health, Helios Klinikum Krefeld Germany
4 shared publicationsAnsgar Schulz
Schwerpunkt Stammzelltransplantation und Immunologie, Klinik für Kinder- und Jugendmedizin, Universitätsmedizin Frankfurt, Frankfurt a. M., Deutschland
3 shared publications
Latest Publications
- 1 October 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (28) , 2751-2752
Optimizing Outcomes After Pediatric Haploidentical Donor Transplant: Role of Graft-Versus-Host Disease Prophylaxis?
- 1 October 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (28) , 2751-2752
Optimizing Outcomes After Pediatric Haploidentical Donor Transplant: Role of Graft-Versus-Host Disease Prophylaxis?
- Open Access
- 10 July 2026
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 37 (7) , e70406
Long‐read sequencing reveals SVA insertion in AP3B1 causing Hermansky–Pudlak syndrome 2
- 10 July 2026
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 37 (7) , e70406
Open AccessLong‐read sequencing reveals SVA insertion in AP3B1 causing Hermansky–Pudlak syndrome 2
- Open Access
- 16 June 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (5) , e20250108
ADA2 genotype and enzyme activity may predict vasculitic or hematologic DADA2 phenotype
Deficiency of adenosine deaminase 2 (DADA2) is an autoinflammatory disease with diverse phenotypes. We describe the genetics, phenotypes, and treatment of n = 48 DADA2 patients from Germany, Austria, and Switzerland. We report a high incidence of hematological (83%) and immunological features (85%), a comparatively low anti-tumor necrosis factor full-response rate (58%), and a high decision probability (21%) for hematopoietic cell transplantation (HCT). We establish a correlation between genetic variant ADA2 activity and patient ADA2 activity. Remarkably, lower patient ADA2 activity is predictive of neutropenia and shows a trend toward HCT decision, whereas higher patient ADA2 activity is predictive of vasculitis symptoms. Genetic variants with low residual ADA2 activity are significantly more common among patients receiving HCT. Our study corroborates previous observations connecting ADA2 activity and clinical phenotype, which up to now have been mainly based on in vitro data.
- 16 June 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (5) , e20250108
Open AccessADA2 genotype and enzyme activity may predict vasculitic or hematologic DADA2 phenotype
Deficiency of adenosine deaminase 2 (DADA2) is an autoinflammatory disease with diverse phenotypes. We describe the genetics, phenotypes, and treatment of n = 48 DADA2 patients from Germany, Austria, and Switzerland. We report a high incidence of hematological (83%) and immunological features (85%), a comparatively low anti-tumor necrosis factor full-response rate (58%), and a high decision probability (21%) for hematopoietic cell transplantation (HCT). We establish a correlation between genetic variant ADA2 activity and patient ADA2 activity. Remarkably, lower patient ADA2 activity is predictive of neutropenia and shows a trend toward HCT decision, whereas higher patient ADA2 activity is predictive of vasculitis symptoms. Genetic variants with low residual ADA2 activity are significantly more common among patients receiving HCT. Our study corroborates previous observations connecting ADA2 activity and clinical phenotype, which up to now have been mainly based on in vitro data.
- Open Access
- 12 May 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (7) , 951-953
Excellent survival after allogeneic HSCT in screened SCID patients and donor type dependent naïve T cell reconstitution
- 12 May 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (7) , 951-953
Open AccessExcellent survival after allogeneic HSCT in screened SCID patients and donor type dependent naïve T cell reconstitution
- 8 May 2026
- Published by Springer Nature in Monatsschrift Kinderheilkunde
- Vol. 174 (6) , 479-485
Neugeborenenscreening auf schwere kombinierte Immundefekte und schwere angeborene T-Zell-Lymphopenien
- 8 May 2026
- Published by Springer Nature in Monatsschrift Kinderheilkunde
- Vol. 174 (6) , 479-485
Neugeborenenscreening auf schwere kombinierte Immundefekte und schwere angeborene T-Zell-Lymphopenien
- Open Access
- 9 April 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (3)
Dominant-negative PSMB10 disrupts immunoproteasome assembly and leads to transient T lymphopenia
Immunoproteasomes are specialized multiprotein proteases that degrade intracellular proteins. Their products serve as peptides for human leukocyte antigen class I presentation playing a key role in antiviral defense and self-tolerance. Monoallelic variants in immunoproteasome genes including proteasome subunit β type 10 have recently been associated with autoinflammatory diseases and severe combined immune deficiency. Their pathophysiological consequences remain poorly understood, and treatment options are scarce. We identified a newborn with severe T lymphopenia and a de novo dominant-negative PSMB10 p.G209R mutation after pathological T cell receptor excision circle newborn screening. We further applied molecular modeling, proteomics, transcriptomics, and ex vivo T lymphopoiesis. Simulations predicted, and biochemical studies confirmed, impaired immunoproteasome assembly and function leading to defective viral sensing and antigen presentation signatures in interferon-treated fibroblasts. Despite this, hematopoietic stem cells differentiated into T cells ex vivo, and the patient developed normal naïve T cell counts and a diverse T cell antigen receptor repertoire within the first year of life in contrast to all previously reported patients.
- 9 April 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (3)
Open AccessDominant-negative PSMB10 disrupts immunoproteasome assembly and leads to transient T lymphopenia
Immunoproteasomes are specialized multiprotein proteases that degrade intracellular proteins. Their products serve as peptides for human leukocyte antigen class I presentation playing a key role in antiviral defense and self-tolerance. Monoallelic variants in immunoproteasome genes including proteasome subunit β type 10 have recently been associated with autoinflammatory diseases and severe combined immune deficiency. Their pathophysiological consequences remain poorly understood, and treatment options are scarce. We identified a newborn with severe T lymphopenia and a de novo dominant-negative PSMB10 p.G209R mutation after pathological T cell receptor excision circle newborn screening. We further applied molecular modeling, proteomics, transcriptomics, and ex vivo T lymphopoiesis. Simulations predicted, and biochemical studies confirmed, impaired immunoproteasome assembly and function leading to defective viral sensing and antigen presentation signatures in interferon-treated fibroblasts. Despite this, hematopoietic stem cells differentiated into T cells ex vivo, and the patient developed normal naïve T cell counts and a diverse T cell antigen receptor repertoire within the first year of life in contrast to all previously reported patients.
- Top Cited PapersOpen Access
- 14 March 2026
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 46 (1)
Syndromic Inborn Errors of Immunity in TREC-Newborn Screening: 5-year Experience from the German Screening Program
TREC-NBS identifies patients with inborn errors of immunity (IEI) and syndromic features, but uncertainty remains regarding their immunological management. To address this, syndromic patients detected by TREC-NBS in Germany between August 2019 and April 2024 were systematically analyzed, including phenotype, treatment, and outcomes. National registries were screened, and data were completed by the treating centres. A total of 77 syndromic patients were identified, with 22 different gene defects found in 72 individuals (93.5%). Primary thymic deficiency was present in 64% (49/77), most commonly due to 22q11.2 deletion syndrome (62%). Common clinical features included congenital heart disease (57%), facial/skeletal abnormalities (53%), and neurological symptoms (36%). Definitive treatments were provided promptly in eligible patients, including 6 thymus transplants and 6 hematopoietic stem cell transplants (HSCT). A watch-and-wait approach was applied to the remaining patients, with 34% (22/65) receiving prophylactic treatment. Recovery of CD3 + T-cell counts was limited to a minority. Overall survival was 89%, with a median follow-up of 32 months (range 0.5–60). To conclude, this is the first comprehensive study of syndromic IEI patients identified through TREC-NBS. The findings show that the German healthcare system enables both early prophylactic care and timely access to definitive therapies. Moving forward, interdisciplinary collaboration will be key to developing evidence-based management guidelines for this challenging patient group.
- 14 March 2026
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 46 (1)
Top Cited PapersOpen AccessSyndromic Inborn Errors of Immunity in TREC-Newborn Screening: 5-year Experience from the German Screening Program
TREC-NBS identifies patients with inborn errors of immunity (IEI) and syndromic features, but uncertainty remains regarding their immunological management. To address this, syndromic patients detected by TREC-NBS in Germany between August 2019 and April 2024 were systematically analyzed, including phenotype, treatment, and outcomes. National registries were screened, and data were completed by the treating centres. A total of 77 syndromic patients were identified, with 22 different gene defects found in 72 individuals (93.5%). Primary thymic deficiency was present in 64% (49/77), most commonly due to 22q11.2 deletion syndrome (62%). Common clinical features included congenital heart disease (57%), facial/skeletal abnormalities (53%), and neurological symptoms (36%). Definitive treatments were provided promptly in eligible patients, including 6 thymus transplants and 6 hematopoietic stem cell transplants (HSCT). A watch-and-wait approach was applied to the remaining patients, with 34% (22/65) receiving prophylactic treatment. Recovery of CD3 + T-cell counts was limited to a minority. Overall survival was 89%, with a median follow-up of 32 months (range 0.5–60). To conclude, this is the first comprehensive study of syndromic IEI patients identified through TREC-NBS. The findings show that the German healthcare system enables both early prophylactic care and timely access to definitive therapies. Moving forward, interdisciplinary collaboration will be key to developing evidence-based management guidelines for this challenging patient group.
- Open Access
- 27 January 2026
- Published by Elsevier in Immunology Letters
- Vol. 279, 107142
FOXN1 immunodeficiency detected by TREC-based newborn screening - A challenge of management?
- 27 January 2026
- Published by Elsevier in Immunology Letters
- Vol. 279, 107142
Open AccessFOXN1 immunodeficiency detected by TREC-based newborn screening - A challenge of management?
- Open Access
- 8 August 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (32) , eadv9650
A human NK cell progenitor that originates in the thymus and generates KIR + NKG2A − NK cells
KIR + NKG2A − natural killer (NK) cells have the unique ability to detect down-regulation of single HLA-I allotypes, frequently occurring in malignantly transformed and virus-infected cells. We have recently shown that circulating innate lymphoid cells 1 (cILC1s) have the potential to generate such KIR + NKG2A − NK cells, but their developmental origin was unknown. Here, we demonstrate that the development of cILC1 is thymus dependent and identify a putative progenitor of cILC1s in the thymus (thyILC1). Single-cell RNA sequencing analysis revealed a close relationship of thyILC1s to CD34 + double-negative thymocytes. Both generated comparable NK cell frequencies, while only thyILC1s could be efficiently differentiated into KIR + NKG2A − NK cells. Last, patients with FOXN1 haploinsufficiency, showing congenital thymic hypoplasia, exhibited a profound deficiency of cILC1s but not cILC2s and cILC3s, demonstrating their specific thymus dependency. Together, the data suggest that thyILC1s are the source of a thymus-dependent NK cell differentiation pathway that promotes generation of KIR + NKG2A − NK cells.
- 8 August 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (32) , eadv9650
Open AccessA human NK cell progenitor that originates in the thymus and generates KIR + NKG2A − NK cells
KIR + NKG2A − natural killer (NK) cells have the unique ability to detect down-regulation of single HLA-I allotypes, frequently occurring in malignantly transformed and virus-infected cells. We have recently shown that circulating innate lymphoid cells 1 (cILC1s) have the potential to generate such KIR + NKG2A − NK cells, but their developmental origin was unknown. Here, we demonstrate that the development of cILC1 is thymus dependent and identify a putative progenitor of cILC1s in the thymus (thyILC1). Single-cell RNA sequencing analysis revealed a close relationship of thyILC1s to CD34 + double-negative thymocytes. Both generated comparable NK cell frequencies, while only thyILC1s could be efficiently differentiated into KIR + NKG2A − NK cells. Last, patients with FOXN1 haploinsufficiency, showing congenital thymic hypoplasia, exhibited a profound deficiency of cILC1s but not cILC2s and cILC3s, demonstrating their specific thymus dependency. Together, the data suggest that thyILC1s are the source of a thymus-dependent NK cell differentiation pathway that promotes generation of KIR + NKG2A − NK cells.
- Open Access
- 17 July 2025
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 1 (3)
Inborn errors of immunity: Manifestation, treatment, and outcome—an ESID registry 1994–2024 report on 30,628 patients
The European Society for Immunodeficiencies patient registry (ESID-R), established in 1994, is one of the world’s largest databases on inborn errors of immunity (IEI). IEI are genetic disorders predisposing patients to infections, autoimmunity, inflammation, allergies, and malignancies. Treatments include antimicrobial therapy, immunoglobulin replacement, immune modulation, stem cell transplantation, and gene therapy. Data from 194 centers in 33 countries capture clinical manifestations and treatments from birth onward, with annually expected updates. This report reviews the ESID-R’s structure, data content, and impact. The registry includes 30,628 patient datasets (aged 0–97.9 years; median follow-up: 7.2 years; total 825,568.2 patient-years), with 13,550 cases in 15 sub-studies. It has produced 84 peer-reviewed publications (mean citation rate: 95). Findings include real-world observations of IEI diagnoses, genetic causes, clinical manifestations, treatments, and survival trends. The ESID-R fosters global collaboration, advancing IEI research and patient care. This report highlights the key role of the multinational ESID-R, led by an independent medical society, in evidence-based discovery.
- 17 July 2025
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 1 (3)
Open AccessInborn errors of immunity: Manifestation, treatment, and outcome—an ESID registry 1994–2024 report on 30,628 patients
The European Society for Immunodeficiencies patient registry (ESID-R), established in 1994, is one of the world’s largest databases on inborn errors of immunity (IEI). IEI are genetic disorders predisposing patients to infections, autoimmunity, inflammation, allergies, and malignancies. Treatments include antimicrobial therapy, immunoglobulin replacement, immune modulation, stem cell transplantation, and gene therapy. Data from 194 centers in 33 countries capture clinical manifestations and treatments from birth onward, with annually expected updates. This report reviews the ESID-R’s structure, data content, and impact. The registry includes 30,628 patient datasets (aged 0–97.9 years; median follow-up: 7.2 years; total 825,568.2 patient-years), with 13,550 cases in 15 sub-studies. It has produced 84 peer-reviewed publications (mean citation rate: 95). Findings include real-world observations of IEI diagnoses, genetic causes, clinical manifestations, treatments, and survival trends. The ESID-R fosters global collaboration, advancing IEI research and patient care. This report highlights the key role of the multinational ESID-R, led by an independent medical society, in evidence-based discovery.